Flagship human AMP — bridges peptide chemistry and host defense.
Also known as: cathelicidin LL-37 · hCAP18 fragment
Part of the Foundational & therapeutic peptides cluster
Overview
LL-37 is the active 37-residue peptide from human cathelicidin, a cornerstone molecule in antimicrobial peptide and innate immunity research.
Source & context
Biological / chemical source: Human cathelicidin (CAMP gene product)
Primary research or clinical context: Innate immunity and infection research; therapeutic development ongoing
Host defense biology
LL-37 exhibits antimicrobial, immunomodulatory, and wound-related activities in experimental systems. Structure–activity work explores amphipathic helices and membrane interaction.
Translation challenges
Like many AMPs, moving from promising biophysics to safe systemic drugs is hard: toxicity, stability, and cost remain active research problems.
FAQ about LL-37
What is LL-37?+
LL-37 is the active 37-residue peptide from human cathelicidin, a cornerstone molecule in antimicrobial peptide and innate immunity research.
Is LL-37 an approved medicine?+
LL-37 is discussed here as a research / educational topic. Innate immunity and infection research; therapeutic development ongoing. This is not medical advice.
What is the typical length of LL-37?+
LL-37 is commonly described as approximately 37 amino acids (Antimicrobial).